Human peripheral blood mononuclear cells display a temporal evolving inflammatory profile after myocardial infarction and modify myocardial fibroblasts phenotype.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 10 2023
Historique:
received: 03 06 2023
accepted: 03 10 2023
medline: 1 11 2023
pubmed: 6 10 2023
entrez: 5 10 2023
Statut: epublish

Résumé

Pathophysiological response after acute myocardial infarction (AMI) is described as a three-stage model involving temporal phenotypic modifications of both immune cells and fibroblasts: a primary inflammatory phase, followed by a reparative phase and a fibrous scar maturation phase. Purinergic receptors, particularly the P2Y11 receptor, have been reported to be involved in the regulation of inflammation after ischemia and could act for the resolution of inflammation after AMI. For the first time, we characterized the immuno-inflammatory and P2Y11 expression profiles of peripheral blood mononuclear cells (PBMC) from AMI patients and analyzed the consequences of presenting these cells to cardiac fibroblasts in vitro. PBMC from 178 patients were collected at various times after reperfused ST-segment elevation AMI, from H0 to M12. Expression level of P2RY11 and genes involved in tolerogenic profile of dendritic cells and T cell polarization were evaluated by RT-PCR. P2Y11 protein expression was assessed by flow cytometry. PBMC and human cardiac fibroblasts (HCF) were cocultured and α-SMA/vimentin ratio was analyzed by flow cytometry. Within the first 48 h after AMI, expression levels of HMOX1, STAT3 and CD4 increased while IDO1 and TBX21/GATA3 ratio decreased. Concomitantly, the expression of P2RY11 increased in both T and B cells. In vitro, PBMC collected at H48 after AMI induced an increase in α-SMA/vimentin ratio in HCF. Our results suggest that human PBMC display an evolving inflammatory profile with reparative characteristics the first two days after AMI and secrete soluble mediators leading to the fibroblastic proteins modification, thus participating to myocardial fibrosis.

Identifiants

pubmed: 37798364
doi: 10.1038/s41598-023-44036-3
pii: 10.1038/s41598-023-44036-3
pmc: PMC10556078
doi:

Substances chimiques

Vimentin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16745

Informations de copyright

© 2023. Springer Nature Limited.

Références

Matrix Biol. 2020 Sep;91-92:167-175
pubmed: 32438054
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Cell Mol Life Sci. 2007 Jun;64(12):1471-83
pubmed: 17375261
Eur Heart J. 2007 Jan;28(1):13-8
pubmed: 17135283
Int J Mol Sci. 2020 Jul 16;21(14):
pubmed: 32708585
Circ Res. 2005 Apr 29;96(8):881-9
pubmed: 15774854
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
JAMA Cardiol. 2021 May 1;6(5):587-592
pubmed: 33146689
Int J Cardiol. 2006 Sep 10;112(1):21-6
pubmed: 16837084
Curr Opin Organ Transplant. 2015 Feb;20(1):37-42
pubmed: 25563990
Med Sci Monit. 2019 Aug 13;25:6034-6042
pubmed: 31407674
Cells. 2022 Apr 20;11(9):
pubmed: 35563692
Cell Signal. 2021 Jan;77:109824
pubmed: 33144186
J Mol Cell Cardiol. 2013 Sep;62:24-35
pubmed: 23644221
Eur J Pharmacol. 2020 Jun 5;876:173060
pubmed: 32142768
Heart Fail Rev. 2011 Jan;16(1):35-47
pubmed: 20407820
J Mol Cell Cardiol. 2018 Aug;121:212-222
pubmed: 30031814
Eur Heart J. 2016 Mar 14;37(11):873-9
pubmed: 26646702
Nat Rev Immunol. 2018 Dec;18(12):733-744
pubmed: 30228378
Circ Res. 2015 Jan 16;116(2):354-67
pubmed: 25593279
Circ Res. 2016 Jun 24;119(1):91-112
pubmed: 27340270
Basic Res Cardiol. 2022 Apr 7;117(1):21
pubmed: 35389088
Cardiovasc Res. 2005 Feb 1;65(2):428-35
pubmed: 15639482
Front Cardiovasc Med. 2019 Jan 10;5:198
pubmed: 30687720
J Immunol. 2015 Jul 15;195(2):651-60
pubmed: 26078273
Br J Pharmacol. 2021 Apr;178(7):1541-1555
pubmed: 33463722
Cell Commun Signal. 2020 Jun 9;18(1):87
pubmed: 32517807
Exp Eye Res. 2016 Jan;142:56-70
pubmed: 26192991
Eur Heart J. 2014 Feb;35(6):376-85
pubmed: 23966310
Int J Mol Sci. 2019 Jul 24;20(15):
pubmed: 31344980
Int J Mol Sci. 2017 Dec 26;19(1):
pubmed: 29278387
Nat Rev Cardiol. 2018 Oct;15(10):601-616
pubmed: 30181596
Front Immunol. 2021 Apr 02;12:664457
pubmed: 33868315
Cell Rep. 2017 Mar 21;18(12):3005-3017
pubmed: 28329691
Circ Res. 2012 Jan 6;110(1):159-73
pubmed: 22223212
Cell Mol Life Sci. 2017 Aug;74(16):2899-2916
pubmed: 28314892
J Thorac Cardiovasc Surg. 2019 Sep;158(3):780-790.e1
pubmed: 30711276
J Clin Invest. 2019 Aug 13;129(11):4922-4936
pubmed: 31408441
Autoimmun Rev. 2015 Jun;14(6):517-27
pubmed: 25633325
Int J Mol Sci. 2022 May 06;23(9):
pubmed: 35563605
Biomedicines. 2021 Feb 18;9(2):
pubmed: 33670488
Basic Res Cardiol. 2014;109(6):444
pubmed: 25248433
Cytokine. 2022 May;153:155848
pubmed: 35301174
Curr Gene Ther. 2019;19(2):110-116
pubmed: 31288720
Int J Cardiol. 2006 Feb 8;107(1):61-6
pubmed: 16337499
Circulation. 2012 Apr 3;125(13):1652-63
pubmed: 22388323
Sci Signal. 2020 Sep 29;13(651):
pubmed: 32994212
Springerplus. 2015 Dec 01;4:744
pubmed: 26693103
Front Immunol. 2019 Aug 09;10:1870
pubmed: 31447857
Cells. 2021 Jul 06;10(7):
pubmed: 34359886

Auteurs

Elodie Miquelestorena-Standley (E)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France. elodie.standley@univ-tours.fr.
Service d'Anatomie et Cytologie Pathologiques, CHRU de Tours, Tours, France. elodie.standley@univ-tours.fr.

Ana Valéria Vinhais da Silva (AVV)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.

Marina Monnier (M)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.

Stéphanie Chadet (S)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.

Marie Piollet (M)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.

Audrey Héraud (A)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.

Roxane Lemoine (R)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.

Thomas Bochaton (T)

Service de Cardiologie, Hospices Civils de Lyon, Lyon, France.

Geneviève Derumeaux (G)

Service de Physiologie, Hôpital Henri Mondor, AP-HP, Université Paris-Est Créteil, INSERM U955, Créteil, France.

Sébastien Roger (S)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.

Fabrice Ivanes (F)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.
Service de Cardiologie, CHRU de Tours, Tours, France.

Denis Angoulvant (D)

EA 4245 Transplantation, Immunologie, Inflammation, Faculté de Médecine, Université de Tours, 10 boulevard tonnele, 37032, Tours Cedex 1, France.
Service de Cardiologie, CHRU de Tours, Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH